Allergic rhinitis is a condition characterized
by inflammation of the nasal passages in response to exposure to allergens,
such as dust, pollen, and pet dander. It affects a significant portion of the
global population and is one of the most common chronic diseases in the world.
The global allergic rhinitis market is expected to grow in the coming years,
driven by factors such as increasing prevalence of allergic rhinitis, rising
awareness about the condition, and the availability of effective treatment
options.
Allergic rhinitis, also
known as hay fever, is a common condition that affects millions of people
worldwide. It is an inflammatory response of the nasal mucosa to airborne
allergens, such as pollen, dust mites, and animal dander, resulting in
symptoms such as sneezing, runny nose, itchy and watery eyes, and nasal
congestion.
Weakening immunity has primarily
contributed to the widespread occurrence of allergy cases globally. Market
reports associated with the healthcare sector made accessible by Market
Research Future along with published reports on other sectors have been lately
put out along with a report on this industry. The market is set to expand at a
CAGR of 3.30% while grossing revenues worth $ 15 billion in the duration of the
forecast period.
Animal dander, mold, pollen, and
dust have been identified as some of the triggering agents for allergic
rhinitis, which are increasingly found at some times of the year as compared to
the rest of the year. Since the degree of control for limiting the contraction
of allergic rhinitis is severely restricted, the measure for controls and
treatment are gaining increasing demand in the market. The treatment and
prevention methods which are handy and provide quick relief are expected to
grow favorably over the forecast period.
Segmental Analysis
The segmentation of the allergic rhinitis market
comprises of types, treatment, and test. The types of the allergic rhinitis
segment consist of perennial, seasonal, and non-allergic rhinitis. On the basis
of the treatment, the segmentation comprises of antihistamines, immunotherapy,
eye drops, decongestants, nasal sprays, sublingual immunotherapy (SLIT) and
home remedies. The antihistamine segment is additionally sub-segmented into
drugs like Xyzal, Clarinex, Allegra, And Zyrtec. The decongestants segment is
further sub-segmented into Sudafed, Sudafed PE, Afrin Nasal Spray, And
Zyrtec-D. The test segment of the market comprises of igE RAST test, skin
tests, and complete blood count.
Detailed Regional Analysis
The regional analysis of the market
comprises of regions such as Europe, America, Asia Pacific along with the
Middle East and Africa. The North American region is controlling the allergic
rhinitis market. The U.S. has the maximum cases of hay fever that are
detected annually. The next major market of allergic rhinitis market is
the European region. The Asia Pacific allergic rhinitis market is currently
observing a high development owing to better awareness about this disease and
its treatment. The growing occurrence of allergic rhinitis in this region is
attributed to the growing population. Japan has the next highest frequency in
terms of cases detected of allergic rhinitis after the US.
Competitive Analysis
The external factors define the
market’s course, which is contingent on the practices and the strategic
roadmaps that are used by the market players. The revolutionary innovations in
products and services are the chief factor contributing to the market's success
and influencing the trends that have gained importance in the market. The
availability of a proficient labor force along with resources is growing the
overall market development. The market is moderately well defined in terms of
its volume and value. The foremost success factors and competitors’
inclinations are increasingly inclined to the strategies being used by market
companies.
The allergic rhinitis market
players are GSK (UK), Sanofi (France), Chong
kun Dang Pharmaceutical Corp. (South Korea), Himalaya (India), J&J (US),
Faes, Farma (Spain), Cigna (USA), Merck (US), Hisamitsu Pharmaceutical Co.in
(Japan), Glenmark Pharmaceutical (India), Ampio pharmaceutical Inc. (US), Olain
Farm (Lavtvia) and others.
Industry Updates:
Aug 2018 Glenmark’s
New Drug Application for Ryaltris which is an investigational fixed-dose
combination nasal spray for periodic allergic rhinitis (SAR) in patients 12
years of age and older. The nasal spray of Ryaltris combines an antihistamine
and a steroid and is also considered Glenmark's foremost respiratory pipeline
runner.
About
Market Research Future:
At Market Research Future (MRFR), we enable our
customers to unravel the complexity of various industries through our Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting
Services. MRFR team have supreme objective to provide the optimum quality
market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research
and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Comments
Post a Comment